Inogen has agreed to divest its US oxygen rental business to Rotech Healthcare, sharpening the respiratory specialist’s core competencies around product innovation.
Under the cash agreement worth up to $25m, Rotech will acquire Inogen’s rental assets, which include portable and home oxygen concentrators used to address respiratory conditions such as chronic obstructive pulmonary disease (COPD). The transaction is expected to close by Q4 2026.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Following the deal’s completion, Inogen will continue to leverage its strengths in respiratory innovation, while partnering with leading home medical equipment providers to expand the number of patients using its products, the company stated.
Alongside the divestment, Inogen has also signed a new long-term supply agreement with the Florida-based company that is intended to support accelerating patient demand and access to its oxygen concentrators through Rotech’s national distribution network. Rotech already has an established home respiratory and medical equipment portfolio.
Inogen’s president and CEO, Kevin Smith, commented: “These transactions strengthen our business and financial profile, sharpen our strategic focus, and enable us to continue investing in innovative solutions that improve patient outcomes.
“Rotech’s strong reputation and respiratory care expertise makes it a proven and trusted partner for our patients.”
Inogen’s product lineup includes its Rove series of portable oxygen concentrators, the latest version of which secured US Food and Drug Administration (FDA) clearance in June 2023, and its SIMEOX 200 airway clearance device.
Inogen’s divestment of its rental business follows declining revenues for the segment, which generated $24.3m in H1 2026, indicative of a year-over-year (YoY) decrease of 9.8%.
Research indicates that COPD cases are rising, with prevalence projected to reach 600 million cases globally by 2050.
Oxygenators are often used in tandem with ventilators to provide breathing support for COPD patients. Elsewhere in the respiratory space, Resmed’s stock declined by 7% after forecasting a soft outlook for FY27. The tempered outlook came in relation to the suspension of sales of the company’s Astral ventilators. The respiratory device landscape has been dogged by several high-profile recalls, including several lines from Philips.
